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Introduction
Prostaglandin E2 (PGE2) is generated by the sequential
metabolism of arachidonic acid by cyclo-oxygenase and
prostaglandin E synthase (1, 2). This lipid mediator has
pleiotropic actions in a range of tissues, including the
immune system (3). Within the immune system, PGE2
modulates the functions of cell populations, such as T
cells and macrophages, which are critical to the
immune response. For example, PGE2 suppresses pro-
liferation of human T cells (4, 5). In macrophages,
PGE2 inhibits production of cytokines such as TNF-α,
and IL-12 (6, 7) and alters antigen presentation by
inhibiting expression of MHC class II proteins (8).
Thus, the overall actions of PGE2 on in vitro models of
cellular immune responses tend to be inhibitory and
suppressive (9). Along with its actions to inhibit cellu-
lar functions, PGE2 may also affect the overall charac-
ter of an immune response. PGE2 may polarize cellular
response toward a Th2 phenotype enhancing IL-4 and
IL-5 production (10, 11) and facilitating immunoglob-
ulin class switching to IgE (12).
These actions of PGE2 can dramatically alter the out-
come of immune responses in the intact organism. For
instance, PGE2 has inhibitory and protective effects in
autoimmune disease. In murine lupus models, adminis-
tration of PGE2 and its analogues improves survival (13,
14). This improvement in survival is accompanied by
reduced auto-Ab production and a substantial reduction
in immune-mediated kidney injury. Similarly, PGE2 may
delay or prevent allograft rejection. In a rat model of kid-
ney transplantation, administration of PGE1 markedly
prolonged graft survival and reduced systemic cellular
alloimmune responses (15). Analogous effects of PGE2
to ameliorate rejection have been observed in animal
models of heart, intestinal, and skin transplantation
(16–19). In human renal transplant recipients, a reduced
number of kidney allograft rejection episodes has also
been reported with PGE2 analogues (20).
The biological actions of PGE2, including its effects on
immunity, are mediated by G protein–coupled receptors,
by convention designated EP (for E prostanoid) receptors
(21, 22). The EP receptors can be divided into four dis-
tinct pharmacological classes, EP1–4, and EP receptors
from each of these subtypes have been cloned and
sequenced (21). The EP receptor isoforms have unique
expression patterns, and they couple to distinct signaling
pathways. The EP1 receptor is coupled to intracellular
calcium, while the EP2 and EP4 receptors are coupled to
G’s and signal by stimulating adenylyl cyclase. Signaling
by the EP3 receptor is more complex. Multiple EP3 recep-
tor isoforms are generated by alternative splicing from a
single EP3 receptor gene, and these EP3 receptor isoforms
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Production of prostaglandin E2 (PGE2) is enhanced during inflammation, and this lipid mediator can
dramatically modulate immune responses. There are four receptors for PGE2 (EP1–EP4) with unique
patterns of expression and different coupling to intracellular signaling pathways. To identify the EP
receptors that regulate cellular immune responses, we used mouse lines in which the genes encoding
each of the four EP receptors were disrupted by gene targeting. Using the mixed lymphocyte response
(MLR) as a model cellular immune response, we confirmed that PGE2 has potent antiproliferative
effects on wild-type responder cells. The absence of either the EP1 or EP3 receptors did not alter the
inhibitory response to PGE2 in the MLR. In contrast, when responder cells lacked the EP2 receptor,
PGE2 had little effect on proliferation. Modest resistance to PGE2 was also observed in EP4–/– respon-
der cells. Reconstitution experiments suggest that EP2 receptors primarily inhibit the MLR through
direct actions on T cells. Furthermore, PGE2 modulates macrophage function by activating the EP4
receptor and thereby inhibiting cytokine release. Thus, PGE2 regulates cellular immune responses
through distinct EP receptors on different immune cell populations: EP2 receptors directly inhibit T
cell proliferation while EP2 and EP4 receptors regulate antigen presenting cells functions.
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couple to different signaling pathways including Gi, Gs,
and calcium. The existence of this family of EP receptors
coupled to distinct intracellular signals provides a molec-
ular basis for the diverse physiological actions of PGE2.
EP receptor isoforms are expressed by the major cel-
lular constituents of the immune system (3). However,
the precise EP receptor isoforms that mediate the
immunoregulatory actions of PGE2 are not known.
Thus, the objective of our studies was to define the
expression of EP receptors by immune cell populations
in the mouse and to determine their contribution to the
regulation of cellular immune responses. Using a com-
bination of pharmacological and genetic approaches,
we find that the actions of PGE2 to suppress antigen-
specific proliferation are complex. To a significant
extent, these actions are mediated by EP2 receptors on
T cells and by EP2 and EP4 receptors on macrophages.
Methods
Animals. The production of mouse lines with targeted
disruptions of the four EP receptor genes are described
elsewhere (23–26). The EP1-deficient line was produced
on an inbred DBA/1 background using an embryonic
stem (ES) cell line derived directly from DBA/1 mice
(25). Thus, controls for the EP1 experiments were age-
matched DBA/1 mice that were purchased from The
Jackson Laboratories (Bar Harbor, Maine, USA). Mice
with targeted mutations of the EP2 and EP3 genes were
produced on a 129/SvEv background. Controls for
these studies were wild type 129/SvEv littermates. On
inbred backgrounds, most EP4-deficient mice die with-
in 24 hours from complications of patent ductus arte-
riosus (24). However, by selective breeding on a mixed
background, EP4-deficient lines have been produced in
which the ductus closes and the animals survive nor-
mally (24). EP4–/– mice from these selected mixed breed-
ings were used in our experiments. Controls for these
studies are wild type littermates. Animals were bred and
maintained in the animal facility of the Durham VA
Medical Centers under the NIH guidelines.
Identification of EP receptor mRNA expression by RT-PCR.
Expression of EP receptor mRNA was assessed by 
RT-PCR as described (27). Splenocyte suspensions
were prepared from wild-type and EP-deficient mice by
gently grinding the spleen between glass slides. The
cells were washed once in PBS and then resuspended
in ice-cold PBS containing 10 mM Tris HCl (pH 7.4),
1% BSA. Splenic T cells were isolated using a commer-
cial separation column (R&D Systems Inc., Min-
neapolis, Minnesota, USA), splenic B cells were isolat-
ed by panning using a polyvalent anti-mouse IgG Ab,
and splenic macrophages were isolated by plastic
adherence. Purity of the cell populations was con-
firmed by cytofluorometry. Total RNA was isolated
from these cell preparations using Tri-Reagent (Sigma
Chemical Co., St. Louis, Missouri, USA), and 0.5 µg
was reverse-transcribed using oligo-dT primers. EP
receptor cDNA was amplified in PCR reactions using
the following primers: EP1 sense 5′-TTAACCTGAGCC-
TAGCGGATG-3′ and anti-sense 5′-CGCTGAGCGTATTG-
CACACTA-3′; EP2 sense 5′-GTGGCCCTGGCTCCCGAA-
AGTC-3′ and anti-sense 5′-GGCAAGGAGCATATGGC-
GAAGGTG-3′; EP3 sense 5′-TGACCTTTGCCTGCAAC-
CTG-3′, EP3α anti-sense 5′-AGCTGGAAGCATAGT-
TGGTG-3′, EP3β anti-sense 5′-GACCCAGGGAAACAGG-
TACT-3′, EP3γ anti-sense 5′-AGACAATGA-GATGGCCT-
GCC-3′; EP4 sense 5′-AGTAGCTAAAGGGGGAA-TCTT-3′,
anti-sense 5′-AACACTTTGGCCTGAACTTGT-3′. The PCR
products were size fractionated on 1.8% agarose in
Tris-borate/EDTA gels, stained with ethidium bro-
mide, and photographed.
Mixed lymphocyte responses. Primary one-way mixed lym-
phocyte responses (MLRs) were performed as described
previously (27). Splenocyte suspensions and isolated T
cells were prepared as described above. Suspensions of
responder splenocytes or T cells were reconstituted at
various concentrations and were mixed with irradiated
stimulator splenocytes from H-2 disparate mice at the
indicated ratios. Fifty microliters of each cell suspension
was added to individual wells of a 96-well plate along
with various concentrations of EP agonists or vehicle.
Plates were incubated at 37°C in a humidified incubator
containing 5% CO2. After varying periods in culture, cells
were pulsed with 0.5 µCi of 3H-thymidine per well for the
final 18 hours of culture. The amount of 3H-thymidine
incorporated in cells was assessed by harvesting cells
onto a glass fiber filtermat using an automated cell har-
vester (Tomtek, Hamden, Connecticut, USA). Filter-
bound radioactivity was measured using a scintillation
counter. Values are expressed as specific counts per
minute, which are calculated from counts in wells with
responders alone subtracted from counts in wells with
responders and stimulators. Within each experiment,
individual conditions were examined in triplicate or
quadruplicate samples.
In some experiments using isolated T cell responders,
purified populations of macrophages were added to the
cultures. To prepare purified cultures of macrophages,
bone marrow was harvested from EP2-deficient and con-
trol mice. B cells and natural killer (NK) cells were
removed from the suspension by sequential panning,
with anti-Ig for B cells and anti-asialo GM1 for NK cells,
followed by complement lysis. The resulting cell popula-
tion was highly enriched for macrophages as determined
by cytofluorometry with MAC-1 and F480 Ab’s. These
pure populations of macrophages were used to reconsti-
tute responder populations in MLR by adding 6 × 104
macrophages to cultures containing 4 × 105 T cells.
Splenic T cells were isolated using a commercial separa-
tion column (R&D Systems Inc.). Allospecific prolifera-
tive responses were then assessed as described above.
Prostanoid compounds used in MLR experiments.
Prostanoid compounds including PGE2, misoprostol,
and sulprostone were obtained from Cayman Chemi-
cal (Ann Arbor, Michigan, USA) as crystalline solids of
greater than or equal to 99% purity. Based on the man-
ufacturer’s recommendations, stock solutions were
prepared in organic solvent (ethanol) and were stored
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at –20°C between experiments. The compounds are
stable in these solutions at this temperature for up to
6 months. For the studies, fresh dilutions were pre-
pared in media on the day of study to produce the
desired experimental concentrations. A similar con-
centration of ethanol vehicle alone was added to the
control cultures.
LPS-stimulated production of TNF-α and IL-12.
Macrophages were prepared by culturing bone marrow
from EP2–/–, EP4–/–, and wild-type mice in Petri dishes
with media supplemented with GM-CSF (30% L929
supernatants). Nonadherent cells were discarded from
these plates after 3 days, and cultures were maintained
in GM-CSF–enriched media for an additional 4–5 days.
Macrophages predominate in these cultures as adher-
ent cells. Purity was confirmed by cytofluorometry
using MAC-1 and F480 Ab’s. Macrophages (4 × 104)
were cultured in 96-well tissue culture plates in the
presence 10 nM LPS along with vehicle or PGE2 in the
indicated concentration. Supernatants were removed
from these wells after 8 and 24 hours. TNF-α produc-
tion was assessed using a bioassay and IL-12 produc-
tion was measured by ELISA.
Statistical analysis. The values for each parameter with-
in a group are expressed as the mean plus or minus the
SEM. For comparisons between EP-deficient and wild-
type groups, statistical significance was assessed using
an unpaired t test for normally distributed data. A paired
t test was used for comparisons within groups. For non-
parametric analyses, a Mann-Whitney U test was used.
Results
EP receptor isoform mRNA expression in murine lymphocyte
subsets. Because there is limited information regarding
expression of EP receptor isoforms by various immune
cell populations in the mouse, we used RT-PCR to
examine EP receptor mRNA in cell populations isolat-
ed from mouse spleen. Using this RT-PCR assay, expres-
sion of EP1 receptor mRNA was easily detected in T and
B lymphocytes, as well as macrophages (data not
shown). Similarly, expression of mRNA for EP2 and EP4
receptors was present in all three splenocyte subsets (not
shown). While all three isoforms of the EP3 receptors
were detected in B cells and macrophages, the α and β
isoforms could not be reproducibly amplified from
splenic T cells (not shown). Thus, with the exception of
α and β isoforms of the EP3 receptor in T cells, mRNA
from all of the known EP receptors was detected in the
major immune cell populations in mouse spleen.
PGE2 analogues suppress proliferative responses of lympho-
cytes to alloantigens. To begin to define the actions of spe-
cific EP receptors to regulate immune responses, we
first examined the effects of PGE2 and several of its ana-
logues upon the MLR, a model of the cellular alloim-
mune response. The MLR is designed to mimic the con-
ditions that might occur in a transplanted organ when
recipient immune cells are activated by recognition of
foreign MHC antigens expressed on the donor tissue.
One-way MLRs were performed using responders from
wild-type (129SvEv) H-2b mice and irradiated stimula-
tors from wild-type (C3H-HeJ) H-2k animals. Prolifera-
tive responses were compared between cultures con-
taining PGE2 analogues and those that received vehicle
alone. The various PGE2-agonists differ in their affini-
ties for EP receptor isoforms (21). PGE2 binds with high
affinity to all four EP receptor subtypes. Misoprostol, at
lower concentrations, exhibits relative specificity for
EP3 and EP4 receptors (Ki = 67 nM), but it may also acti-
vate EP1 and EP2 receptors at higher concentrations 
(Ki = 120–250 nM) (21). Sulprostone, on the other hand,
is a relatively specific agonist for the EP1 (Ki = 21 nM)
and EP3 receptors (Ki = 0.6 nM) (21).
As depicted in Figure 1, PGE2, among the compounds
tested, caused the most potent inhibition of the cellu-
lar immune response; concentrations of 5–10 nM
caused 50% inhibition of proliferation. Although miso-
prostol also inhibited the MLR, it was significantly less
potent than PGE2, requiring almost log dose-higher
concentrations to produce 50% inhibition. In contrast,
concentrations of sulprostone up to 50 µM did not
substantially affect the vigor of the proliferative
response. These data confirm the actions of PGE2 to
suppress cellular immune responses and suggest that
EP2 and/or EP4 receptors may mediate these effects.
Identification of EP receptors that inhibit MLR using geneti-
cally altered mice. To more precisely identify the EP
receptor isoforms that regulate proliferation in MLR,
we compared the actions of PGE2 upon responder cell
populations derived from mice with targeted disrup-
tion of each of the individual EP receptor genes. Figure
2 summarizes the results of experiments with EP1-defi-
cient (Figure 2a), EP3-deficient (Figure 2b), and EP4-
deficient (Figure 2c) responders. PGE2 caused potent
inhibition of allospecific proliferation by the EP1- and
EP3-deficient splenocytes, and this effect was virtually
identical to that observed in their respective wild-type
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Figure 1
Effects of PGE2 analogues on proliferation in the MLR. A range of con-
centrations of PGE2, misoprostol, and sulprostone were added to the
MLR, and their effects on proliferation were determined. The data are
expressed as a percentage of the control response in MLR with vehi-
cle alone. The agonist concentrations are shown on the x-axis as log
10 nM. PGE2 and misoprostol caused significant inhibition of the
response. *P < 0.001 vs. media alone; ‡P < 0.001 vs. misprostol.
controls. In the lower concentration range, the
inhibitory actions of PGE2 on EP4-deficient cells were
also similar to controls. However, at concentrations of
100 nM and above, the absence of EP4 receptors was
associated with a modest, but significant reduction in
sensitivity to the antiproliferative effects of PGE2. By
contrast, as depicted in Figure 3, EP2-deficient respon-
ders were markedly resistant to the inhibitory actions
of PGE2. At the lowest concentrations, PGE2 had no
effect on proliferation of the EP2-deficient cultures. At
higher concentrations of PGE2 that inhibited more
than 60% of the response in wild-type cultures, only
modest inhibition of the EP2-deficient responders was
observed. These data indicate that EP2 receptors
expressed by the responder population mediate most
of the actions of PGE2 to inhibit cellular immune
responses in the MLR.
MLR with purified T cells. In our initial experiments, we
studied responder cells consisting of a mixed population
of splenocytes including T cells, B cells, and macro-
phages. Since all of these cell populations express vari-
ous EP receptor isoforms, including EP2, EP-recep-
tor–mediated effects in any or all of these cells might
contribute to the actions of PGE2 to modulate the cellu-
lar response to alloantigens. To determine whether PGE2
influences allospecific proliferation by direct effects on
T cells and to examine the role of the EP2 receptor in
these actions, we performed additional MLR experi-
ments using isolated T cells as responders. As shown by
Figure 4 and similar to its actions on mixed splenocyte
responders, PGE2 caused significant inhibition of the
MLR when the responders were a purified population of
T cells isolated from wild-type mice. In marked contrast,
concentrations of PGE2 up to 30 µM had no effect on
proliferation of isolated EP2-deficient T cells. Compared
with the mixed population of EP2-deficient splenocytes,
EP2-deficient T cells had a more complete resistance to
PGE2. The difference in PGE2 responsiveness between
EP2–/– mixed splenocytes and isolated T cells suggests a
contribution of other (non-T cell) populations to the
regulatory actions of PGE2 in the MLR.
Distinct actions of PGE2 on T cells and macrophages. To
determine whether EP receptors on macrophages
might contribute to the regulation of cellular immune
responses by PGE2, we performed reconstitution exper-
iments with macrophages and isolated T cells. MLR
cultures were set up with T cells from EP2-deficient
splenocytes in the presence of exogenous PGE2 
(Figure 5). Some of the cultures were reconstituted
with macrophages derived from wild-type or EP2-defi-
cient mice. As shown previously, EP2-deficient T cells
alone were completely resistant to the actions of PGE2.
Addition of syngeneic EP2+/+ macrophages restored
some sensitivity to the antiproliferative actions of
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Figure 2
PGE2 inhibits proliferation in MLR with EP1-, EP3-, and EP4-deficient
lymphocytes. MLR experiments were performed comparing respon-
ders that were lacking (a) EP1, (b) EP3, and (c) EP4 receptors with
their respective wild-type controls. On the x-axis the effects of vari-
ous concentrations of PGE2 upon proliferation were determined. The
data are expressed as a percentage of the control response in MLR
with vehicle alone. *P = 0.008 vs. EP4+/+.
Figure 3
EP2-deficient lymphocytes are resistant to the antiproliferative
actions of PGE2 in the MLR. MLR experiments were performed com-
paring responders that were lacking EP2 receptors with their respec-
tive wild-type controls. On the x-axis, the effects of various concen-
trations of PGE2 upon proliferation were determined. The data are
expressed as a percentage of the control response in MLR with vehi-
cle alone. *P = 0.004 vs. EP2+/+; **P < 0.0001 vs. EP2+/+.
PGE2. Inhibitory actions of PGE2 were also conferred
by EP2–/– macrophages, but the magnitude of inhibi-
tion was less prominent than with EP2+/+ macrophages
(13% vs. 27%; P = 0.03). These data suggest that EP
receptors on autologous macrophages contribute to
the regulation of the cellular alloimmune response.
EP receptors that regulate cytokine release by macrophages.
Macrophages shape cellular immune responses in their
capacity as antigen-presenting cells and by producing a
variety of cytokines that can influence the proliferation
and function of antigen-specific T cells. Because of this
central role, along with our data implicating EP recep-
tors on macrophages in modulating the alloimmune
response, we examined the relative contributions of EP2
and EP4 receptors to the regulation of macrophage
function. We focused on two cytokines, TNF-α and 
IL-12, which are known to regulate T cell function. As
shown in Figure 6, PGE2 caused dose-dependent inhi-
bitions of TNF-α and IL-12 release in LPS-stimulated
wild-type cells, with substantial reductions in cytokine
release at concentrations greater than 30 nM PGE2. In
the EP2-deficient macrophages, the inhibitory actions
of PGE2 were virtually identical to those seen in the
wild-type cells with 50% inhibition of cytokine release at
concentrations of 1–3 nM PGE2. In contrast, EP4-defi-
cient macrophages were more resistant to the inhibito-
ry actions of PGE2 upon IL-12 release (Figure 6a). Fur-
thermore, across the concentration range tested, PGE2
had no detectable effect on TNF-α production by EP4-
deficient, LPS-stimulated macrophages (Figure 6b).
Discussion
The actions of PGE2 to regulate immune responses have
been long recognized. PGE2 modulates a wide range of
T cell functions, and these actions are largely suppres-
sive or inhibitory (3). For example, PGE2 inhibits anti-
gen-induced proliferation, cytokine production, and
cell surface expression of cytokine receptors (9). A vari-
ety of effector functions are also inhibited by PGE2,
including the development of antigen-specific cytotox-
ic T cells (28). The capacity of PGE2 to suppress many of
the responses that are triggered by T cell receptor acti-
vation suggests that it acts at a central site in the bio-
chemical cascade associated with T cell receptor stimu-
lation. In this regard, Paliogianni and associates found
that PGE2 antagonizes the actions of calcineurin phos-
phatase to stimulate the transcription of cytokine genes
(29), such as the IL-2 and IFN-γ genes, that are an
important part of the genomic activation program in T
cells. The inhibition of IL-2 and IFN-γ by PGE2 may also
contribute to its ability to skew cellular responses
toward a Th2 phenotype.
These inhibitory actions of PGE2 upon T cell functions
can impact immune responses in the whole animal. In
murine models of autoimmune disease, chronic adminis-
tration of PGE2 has dramatic effects to ameliorate the
manifestations of autoimmunity and to prevent immune-
mediated end organ injury (13, 14). Likewise, PGE2 and its
analogues dramatically suppress rejection of organ and
tissue transplants (15–19). In some models, long-term
allograft survival can be induced by treatment with PGE2
and no other immunosuppressive therapy. Beneficial
effects of E-series prostanoids in human transplant recip-
ients have also been reported (20, 30, 31). Nonetheless, the
precise role of individual EP receptor isoforms in mediat-
ing these actions is not clear. Because of the potent actions
of PGE2 to inhibit transplant rejection, we chose to first
examine the role of EP receptor isoforms in the MLR, an
in vitro model of the cellular alloimmune response.
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Figure 4
Comparison of PGE2 effects on allospecific proliferation of EP2-defi-
cient mixed splenocytes and T cells. MLR experiments were per-
formed comparing responders that were lacking EP2 receptors (filled
bars) with their respective wild-type controls (open bars). Respon-
der cells were either unseparated populations of mixed splenocytes
(left) or T cells that had been purified from the spleen (right).
Allospecific proliferation was measured in the presence of 30 nM
PGE2 or vehicle. The data are expressed as percentage of inhibition
compared with the MLR with vehicle alone. *P < 0.001 vs. EP2+/+.
Figure 5
Relative contributions of T cells and macrophages to the inhibitory
actions of PGE2 in the MLR. MLR experiments were performed using
T cells isolated from spleens of EP2-deficient mice. In some studies,
bone marrow macrophages from EP2+/+ or EP2–/– mice were added
to the cultures as indicated. Allospecific proliferation was measured
in the MLR in the presence or absence of 10 nM PGE2. The data are
expressed as percentage of inhibition compared with the correspon-
ding control MLR with vehicle alone. WT, wild-type; APC, antigen
presenting cells.
Our studies using genetically manipulated mice indi-
cate that the regulatory actions of PGE2 in cellular
immunity are complex, involving more than one recep-
tor and different immune cell populations. Our data
show that the EP2 receptor is a dominant mediator of
the inhibitory actions of PGE2 in the MLR. In T cells,
absence of the EP2 receptor confers a resistance to PGE2
that is virtually absolute. It is possible that the deletion
of the EP2 receptor may have uncovered stimulatory
actions of other EP receptors, such as EP3, that might
contribute to the apparent resistance of EP2-deficient
cells to PGE2. However, no exaggerated effect of PGE2
was observed in the EP3-deficient cells, which would be
expected if the EP3 receptor has a major effect to antag-
onize EP2 signaling in this circumstance. Thus, despite
the presence of multiple EP isoforms in T cells, the Gs-
linked EP2 receptor alone seems to mediate the inhibi-
tion of antigen-specific proliferation by PGE2. This find-
ing is consistent with previous work showing that many
of the inhibitory actions of PGE2 upon T cells can be
reproduced by cAMP or maneuvers that increase intra-
cellular cAMP concentration (15, 29, 32). Although EP4
receptors are also expressed by murine T cells and these
receptors also couple to adenylyl cyclase, our studies
indicate that EP4 receptors do not directly modulate
antigen-stimulated proliferation of T cells. At this point,
our findings are most clearly relevant to murine systems.
It is possible that there may be differences in expression
and functions of EP receptors in human leukocytes.
While recognition of antigens by T cells initiates and
drives cellular immune responses, macrophages also play
several critical roles. They can efficiently present peptide
antigens to the T cell in the context of MHC class II pro-
teins and provide additional costimulatory signals that
are required for T cell activation. In addition,
macrophages produce a variety of cytokines and other
mediators that shape the T cell response. PGE2 has the
capacity to inhibit or suppress many of these
macrophage functions. For example, PGE2 inhibits
expression of MHC class II proteins (8) and thus may
interfere with antigen-presenting functions of the
macrophage. Cytokine production is likewise inhibited
by PGE2 (6, 7). Our studies have demonstrated that the
actions of PGE2 to suppress cytokine production by
macrophages are mediated almost exclusively by the EP4
receptor; PGE2 has no effect on LPS-stimulated cytokine
release in EP4-deficient macrophages. In MLR, enhanced
production of cytokines such as TNF-α and IL-12 con-
tributes to the vigor of the proliferative response (33, 34),
and therefore suppression of monokine production by
PGE2 might contribute to the overall actions of PGE2 to
reduce proliferation. The modest resistance of EP4-defi-
cient mixed splenocytes to PGE2 may be explained by a
failure to inhibit TNF-α and/or IL-12 production by
macrophages. If so, the apparent contribution of this
pathway to the overall actions of PGE2 in the MLR is rel-
atively small. However, in other circumstances where
monokine production has a more critical role, the
inhibitory actions of EP4 receptors may have more pro-
found consequences. Furthermore, IL-12 production by
antigen-presenting cells drives CD4+ T cell differentia-
tion toward the Th1 phenotype (35). Accordingly, inhi-
bition of IL-12 production by PGE2 may contribute to
its propensity to promote Th2 responses.
Along with regulation of cytokine release, the recon-
stitution MLR experiments suggest other actions of
PGE2 in the macrophage that modulate cellular immu-
nity. In these studies (Figure 5), the addition of
macrophages to the cultures of EP2-deficient T cells par-
tially restored the inhibitory actions of PGE2 on alloanti-
gen-induced proliferation. These findings are most con-
sistent with active suppression and suggest that PGE2
may induce a factor in macrophages that inhibits the
MLR. As the magnitude of suppression was less with
EP2-deficient compared with wild-type macrophages,
the EP2 receptor seems to contribute to this activity.
Because of the mixed genetic background of the EP4-
deficient mice, an analogous reconstitution experiment
to determine the contribution of the EP4 receptor could
not be carried out. Nonetheless, our findings suggest
that the macrophage plays a complex role in mediating
inhibitory actions of PGE2 in cellular immunity. Fur-
thermore, in the macrophage as in the T cell, EP2 and
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Figure 6
The EP4 receptor mediates inhibitory actions of PGE2 on cytokine
release by macrophages. Bone marrow macrophages were isolated
from EP2+/+, EP2–/–, EP4+/+, and EP4–/– mice. The macrophages were
stimulated with 10 nM LPS, and various concentrations of PGE2 were
added (x-axis). Supernatants were collected, and release of IL-12 (a)
and TNF-α (b) were measured. For clarity, the x-axis in a is expressed
as log 10 nM. EP4–/–, but not EP2–/–, macrophages were resistant to
the actions of PGE2 to inhibit cytokine release. **P < 0.001 vs. EP4+/+.
EP4 receptors have divergent functions despite their sim-
ilar intracellular signaling pathways. A mechanism to
explain this apparent compartmentalization of signal-
effector coupling remains to be defined.
Our studies have identified distinct actions of differ-
ent EP receptor isoforms to regulate cellular immune
responses. These receptors, EP2 and EP4, therefore rep-
resent potential targets for immunomodulatory thera-
pies. Although the immunosuppressive actions of PGE2
are well recognized, problematic side effects related to
its broad biological activities along with difficult phar-
macokinetics have made it impractical to use as a ther-
apeutic agent. Identification of small molecules that
interact specifically with immunoregulatory EP recep-
tor isoforms may allow a wider, more practical exploita-
tion of these pathways in the therapy of autoimmune
diseases and transplant rejection. The distinct separa-
tion of functions of these receptors within individual
cells provides a potential mechanism for modulating
immune responses with relatively fine specificity affect-
ing a range of immunological functions.
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